Arvinas

Youtube Subscribe

Open: 45.14 Close: 45.97 Change: 0.83

Our AI found some flaws in Arvinas.

The game is changing. There is a new strategy to evaluate Arvinas fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Arvinas are: Goldman, Sachs, initiate, Arvinas, buy, coverage, rating, and the …

Concept Map

Semantic Network

Stock Summary

Arvinas, Inc. engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that.

Today's Summary

Goldman Sachs initiated coverage on Arvinas with a buy rating and price target of $70. Goldman Sachs: Breast cancer drug vepdegestrant (ARV-471) presents an underappreciated commercial opportunity. The firm initiated coverage with a Buy rating and a 12-month target. Arvinas, Inc. serves health care industry worldwide. Arvinis is a clinical-stage biotechnology company dedicated to improving the lives of patients. Goldman Sachs initiates Arvinas as buy Goldman Sachs said in its initiation of the biotech company that it sees an attractive risk/reward for Arvin as buy. Goldman Sachs gives this innovative cancer-fighting biotech nearly 70% upside.

Today's News

Goldman Sachs initiated coverage on Arvinas with a buy rating and price target of $70. Goldman Sachs: Breast cancer drug vepdegestrant (ARV-471) presents an underappreciated commercial opportunity. The firm initiated coverage with a Buy rating and a 12-month target. Arvinas, Inc. serves health care industry worldwide. Arvinis is a clinical-stage biotechnology company dedicated to improving the lives of patients. Goldman Sachs initiates Arvinas as buy Goldman Sachs said in its initiation of the biotech company that it sees an attractive risk/reward for Arvin as buy. Goldman Sachs gives this innovative cancer-fighting biotech nearly 70% upside.

Stock Profile

"Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut."

Keywords

Are looking for the most relevant information about Arvinas? Investor spend a lot of time searching for information to make investment decisions in Arvinas. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Arvinas are: Goldman, Sachs, initiate, Arvinas, buy, coverage, rating, and the most common words in the summary are: arvinas, best, stock, company, bloomberg, job, top, . One of the sentences in the summary was: Goldman Sachs initiates Arvinas as buy Goldman Sachs said in its initiation of the biotech company that it sees an attractive risk/reward for Arvin as buy. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #arvinas #best #stock #company #bloomberg #job #top.

Read more →

Youtube Subscribe

---